Tìm theo
Adalimumab
Các tên gọi khác (1) :
  • Ig gamma-1 chain C region
antirheumatic agents, anti inflammatory agents, immunosuppressive agents
Thuốc Gốc
Biotech
CAS: 331731-18-1
ATC: L04AB04
ĐG : Abbott Laboratories Ltd. , http://www.abbott.com
CTHH: C6428H9912N1694O1987S46
PTK: 144190.3000
Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C6428H9912N1694O1987S46
Phân tử khối
144190.3000
Độ kỵ nước
-0.441
Điểm đẳng điện tích
8.25
Dược Lực Học : Used in the treatment of immune system mediated diseases, adalimumab binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting tissue destruction.
Cơ Chế Tác Dụng : Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons. Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.
Dược Động Học :

▧ Metabolism :
Most likely removed by opsonization via the reticuloendothelial system.
▧ Half Life :
10-20 days.
▧ Clearance :
* 12 mL/hr [RA patients with dose 0.25-10 mg/kg]
Chỉ Định : For treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
Tương Tác Thuốc :
  • Canakinumab Increases immunosuppressive effects and risk of infection.
  • Infliximab Both bind to TNF alfa and thus combination results in enhanced immunosuppressive effect. It is recommended that simultaneous use of both agents be avoided.
  • Rilonacept results in increased immunosuppressive effects; increases the risk of infection.
  • Tofacitinib Adalimumab (and other anti-TNF immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression. It is recommended to avoid concurrent therapy.
  • Trastuzumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Liều Lượng & Cách Dùng : Solution - Subcutaneous
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00051
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0074-3799-02
GenBank
http://www.ncbi.nlm.nih.gov/nuccore/J00228
PharmGKB
http://www.pharmgkb.org/drug/PA10004
Wikipedia
http://en.wikipedia.org/wiki/Adalimumab
RxList
http://www.rxlist.com/cgi/generic3/humira.htm
Drugs.com
http://www.drugs.com/cdi/adalimumab.html
... loading
... loading